// App-Quantinova.ai

: CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer 89Zr-Crefmirlimab Berdoxam

Researchers

Presenter

  • Martin Hutchings

Principal Investigators

  • Wendy Osborne

  • George Petrides

  • Fritz Offner

  • Ciel De Vriendt

  • Giuseppe Gritti

  • Roberto Boni

  • William Townsend

  • Irfan Kayani

  • Ian Wilson

  • Yanjie Wang

  • Maria Jadhav

  • Cristina Santini

  • Claire Kelly

  • Martin Kornacker

  • Jean J.L. Tessier

  • Ann-Marie E Bröske

  • Angelika Lahr

  • Axel Boehnke

  • Christoph M. Griessinger

Medical Centers

  • Rigshospitalet, Copenhagen, Denmark

  • Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China

  • Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

  • Ospedale Papa Giovanni XXIII, Bergamo, Italy

  • University College London Hospital Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom

  • Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

Locations

  • United Kingdom

  • Denmark

  • Germany

  • China

  • Belgium

  • United States

  • Switzerland

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • B-Cell Non-Hodgkin Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Fixed Dose

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved